has been cited by the following article(s):
|
[1]
|
Features of the bone metabolism in primary hyperparathyroidism
Russian Journal of Preventive Medicine,
2024
DOI:10.17116/profmed202427091130
|
|
|
|
|
[2]
|
Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis
Frontiers in Endocrinology,
2023
DOI:10.3389/fendo.2023.1098841
|
|
|
|
|
[3]
|
Draft of clinical guidelines for the diagnosis and treatment of primary hyperparathyroidism in adult patients
Endocrine Surgery,
2023
DOI:10.14341/serg12790
|
|
|
|
|
[4]
|
Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency
Endocrine,
2023
DOI:10.1007/s12020-023-03381-z
|
|
|
|
|
[5]
|
The clinical practice guidelines for primary hyperparathyroidism, short version
Problems of Endocrinology,
2021
DOI:10.14341/probl12801
|
|
|
|
|
[6]
|
Anatomy, Posture, Prevalence, Pain, Treatment and Interventions of Musculoskeletal Disorders
2018
DOI:10.5772/intechopen.74034
|
|
|
|
|
[7]
|
Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review
Frontiers in Endocrinology,
2017
DOI:10.3389/fendo.2017.00079
|
|
|
|